Cidara Therapeutics Announces Presentation of Data from its Antifungal Drug Development Programs at ECCMID 2016
Presentations to Highlight Results from the Phase 1 Study of Novel Echinocandin CD101 IV Demonstrating Excellent Safety and Supporting Once-Weekly Dosing
“Cidara’s presentations at this year’s ECCMID reinforce our commitment
to developing novel antifungal therapies to fight serious infections
that are becoming increasingly resistant to current standards of care,”
said
The ECCMID presentations are as follows:
Oral Presentations:
- Cidara Pipeline; T. Sandison
- O425: The safety and single-dose pharmacokinetics of CD101 IV: results from a phase 1, dose-escalation study; D. Thye
Poster Presentation:
- P1578: Allometric scaling and the chimpanzee as a surrogate for human pharmacokinetics of CD101, a novel echinocandin; V. Ong
About
Cidara is a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel anti-infectives
for the treatment of diseases that are inadequately addressed by current
standard-of-care therapies. Cidara's initial product portfolio comprises
two formulations of the company's novel echinocandin, CD101. CD101 IV is
being developed as a once-weekly high exposure therapy for the treatment
and prevention of serious, invasive fungal infections. CD101 topical is
for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC
(RVVC), a prevalent mucosal infection. In addition, Cidara has developed
a proprietary immunotherapy platform, Cloudbreak™, designed to create
compounds that direct a patient's immune cells to attack and eliminate
pathogens that cause infectious disease. Cidara is headquartered in
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, long-acting nature,
anticipated human dosing and other attributes of CD101 IV and CD101
topical, and their potential to treat infections, as well as the
intended design of current and future Cloudbreak compounds. Risks that
contribute to the uncertain nature of the forward-looking statements
include: the success and timing of Cidara’s preclinical studies and
clinical trials; regulatory developments in
View source version on businesswire.com: http://www.businesswire.com/news/home/20160406005086/en/
Source:
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H. Uhl
Managing
Director
858-356-5932
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Mike Beyer
312-961-2502
mikebeyer@sambrown.com